Skip to main content

Day: March 23, 2021

AIS Resources Acquires 20% Equity Interest in Tech One Lithium Resources Corp. Incahuasi Lithium Salar, Argentina

VANCOUVER, British Columbia, March 23, 2021 (GLOBE NEWSWIRE) — A.I.S. Resources Limited (TSX: AIS, OTCQB: AISSF) (the “Company” or “AIS”) is delighted to report that AIS Resources has acquired from Tech One Lithium Resources Corp. a 20% interest in Mining Licence File Number 23262 (Candela II) covering 3 sq km on the Incahuasi Salar in the lithium triangle in Argentina. The Candela II licence neighbours Gangfeng Lithium, China’s largest producer of the battery metal and Orocobre, a lithium producer in Argentina. Tech One Lithium Resources Corporation (“Tech One”), a private company, has optioned the Exploration license for 12 months to complete due diligence and further exploration work, and has the right to acquire 100% of the property for USD one million dollars (CAD1.3 million). The option fee paid by...

Continue reading

Cipla Therapeutics and SIGA Technologies Announce Strategic Partnership to support innovation and provide access to novel antibacterial drugs against biothreats

NEW YORK, March 23, 2021 (GLOBE NEWSWIRE) — Cipla Therapeutics, a division of Cipla USA Inc., an affiliate of Cipla Limited (BSE: 500087; NSE: CIPLA EQ; referred to as “Cipla”) and SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market announced entering into a strategic partnership to deliver sustained innovation and access to novel antibacterial drugs, particularly against biothreats. The World Health Organization has declared that anti-microbial resistance (AMR) one of the top 10 global public health threats facing humanity2 which puts at risk the effective prevention and treatment of a wide range of infections. According to the AMR Industry Alliance, a global AMR private sector coalition, AMR is the ability of a microorganism (such as bacteria,...

Continue reading

DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceutical’s Lead Drug, CRV431

EDISON, N.J., March 23, 2021 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”) – driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and liver disease, today announced positive results from an in vivo study of CRV431 in a Diet-Induced Animal Model Of Non-alcoholic fatty liver Disease (“DIAMOND”).1 It is estimated by the National Institutes of Health, that between 3% – 12% of the U.S. adult population has NASH.2 There are currently at least 90 drug candidates targeting NASH in various stages of development.3 The majority of these drug candidates are designed to target metabolic perturbations leading to the pathogenesis of NASH and thereby seek to normalize glycemic control,...

Continue reading

FAX Capital Closes Acquisition of Carson Dunlop and Appoints Graham Badun as CEO of New Platform Company

NOT FOR DISSEMINATION IN THE UNITED STATES OR DISTRIBUTION TO U.S. NEWS WIRE SERVICES TORONTO, March 23, 2021 (GLOBE NEWSWIRE) — FAX Capital Corp. (the “Company” or “FAX Capital”) (TSX: FXC and FXC.WT) today announced that it has, through its wholly owned subsidiary, completed its previously announced $11.75M acquisition of an approximate 78 per cent controlling interest in Carson, Dunlop & Associates Ltd. (“Carson Dunlop”). The acquisition was financed through the Company’s available cash balance (all currency figures are in Canadian dollars). FAX Capital also announced today that it has appointed Graham Badun as Chief Executive Officer of its new platform company, which will leverage Carson Dunlop as its foundational asset as it focuses on organic growth initiatives and acquisition opportunities of complementary businesses...

Continue reading

Gene Therapy Market Size 2021 | To Exhibit 33.6% CAGR and Hit USD 35.67 billion by 2027

Pune, India, March 23, 2021 (GLOBE NEWSWIRE) — The global gene therapy market is set to gain momentum from the rising incidence of different types of cancer. The field of this therapy is undergoing several technological advancements that would help in treating cancer in those patients who are at high risks of getting affected by this disease through genetic mutations. “The report further mentions that the market size was USD 3.61 billion in 2019 and is projected to reach USD 35.67 billion by 2027, exhibiting a CAGR of 33.6% during the forecast period” The U.S. to Dominate Owing to Presence of Favorable Policies In 2019, the U.S. generated USD 2.16 billion in terms of revenue. The country is expected to dominate throughout the coming years stoked by the increasing usage of advanced gene therapies for the treatment of rare conditions....

Continue reading

Proposed Amendment to the Principal Amount of the Affected Securities Meeting of the Etp Securityholders

23 March 2021 LEI: 2138003QW2ZAYZODBU23 LSE Code: QQQS WISDOMTREE MULTI ASSET ISSUER PUBLIC LIMITED COMPANY(a public company incorporated with limited liability in Ireland)WISDOMTREE NASDAQ 100® 3X DAILY SHORT SECURITIESISIN:IE00BLRPRJ20 PROPOSED AMENDMENT TO THE PRINCIPAL AMOUNT OF THE AFFECTED SECURITIESMEETING OF THE ETP SECURITYHOLDERS THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about what action you should take, you are recommended to consult your independent financial adviser. NOTICE is hereby given that, pursuant to the provisions of the trust deed dated 30 November 2012 (as amended) constituting (inter alia) the WisdomTree NASDAQ 100® 3x Daily Short  Securities (the “Affected Securities”) and made between (1) WisdomTree Multi Asset Issuer Public Limited Company (the “Issuer”), (2) The...

Continue reading

Offentliggørelse af indre værdi

På grund af tekniske vanskeligheder er det p.t. ikke muligt at offentliggøre indre værdier via de almindelige distributionskanaler. De offentliggøres derfor på denne vis, indtil de tekniske problemer er løst Indre værdi er oplyst i skema nedenfor indeholdende oversigt over samtlige foreninger og afdelinger under vores administration. Eventuelle henvendelser vedrørende denne meddelelse kan rettes til undertegnede på telefon 3814 6600. Med venlig hilsenInvest Administration A/S Niels Erik Eberhard DirektørOMX Short Name Navn ISIN Indre VærdiInvesteringsforeningen Gudme Raaschou  GRIEHY European High Yield DK0016205255 113,03GRIUSHY US High Yield DK0060477859 100,57GRIEMA Emerging Markets Aktier DK0060184083 118,52GRIEMD Emerging Markets Debt DK0060260602 87,27GRIEJD Europæiske Ejendomsaktier DK0061133899 105,83Investeringsforeningen...

Continue reading

Frontier Announces Launch of Initial Public Offering

DENVER, March 23, 2021 (GLOBE NEWSWIRE) — Frontier Group Holdings, Inc. (“Frontier”) today announced the launch of its initial public offering of 30 million shares of its common stock. The offering consists of 15 million shares of common stock offered by Frontier and 15 million shares of common stock to be sold by certain of Frontier’s existing stockholders. Frontier will not receive any proceeds from the sale of the shares by the selling stockholders. A selling stockholder intends to grant the underwriters a 30-day option to buy an additional 4.5 million shares of common stock from such selling stockholder at the initial public offering price, less the underwriting discount and commissions. The initial public offering price is currently expected to be between $19 and $21 per share. Frontier intends to list its common stock on the...

Continue reading

Liquidia Corporation Reports Full-Year 2020 Financial Results and Provides Corporate Update

–  Integrated RareGen (now known as Liquidia PAH) to establish commercial presence in PAH–  Clarified path towards submitting response to CRL for LIQ861 in mid-2021–  Reducing net annual spending more than 40% in 2021 compared to 2020 cash burn–  Company to host webcast and conference call today at 8:30 a.m. ET RESEARCH TRIANGLE PARK, N.C., March 23, 2021 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the full-year ended December 31, 2020. The Company will host a webcast and conference call at 8:30 a.m. ET to discuss the 2020 financial results and provide a corporate update. Damian deGoa, Liquidia’s Chief Executive Officer, said: “Activity level has been high. We closed the acquisition and integration of RareGen, LLC, now known as...

Continue reading

AC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D Outlook

Anti-pTau Alzheimer’s vaccine delivers potent immunogenicity in ongoing Phase 1b/2a study, supporting further development into Phase 2/3Anti-Abeta Alzheimer’s vaccine advancing based on Phase 1b safety and immunogenicity results in Down syndrome; further interim results expected in Q2 for Phase 2 in Alzheimer’s disease Morphomer™ Tau aggregation inhibitor achieves target brain exposure in Phase 1; program advancing in NeuroOrphan indications and Alzheimer’s disease First-in-class alpha-synuclein PET diagnostic to report clinical results in Q3 2021 Advancing multiple candidates targeting the NLRP3 inflammasome pathway for CNS and non-CNS indications Ongoing strong financial position of CHF 225.9 million in cash ensures the Company is fully financed through Q1 2024, excluding potential incoming milestonesLAUSANNE, Switzerland, March...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.